Literature DB >> 31151776

Primary prevention of ROP and the oxygen saturation targeting trials.

Brian A Darlow1, Shahid Husain2.   

Abstract

Reducing the burden of visual morbidity from retinopathy of prematurity (ROP) begins with primary prevention, and improvements in neonatal care with a positive impact on ROP are possible in all settings. Strategies range from rigorous adoption of inexpensive evidence-based protocols, for example on temperature control, prevention of sepsis and support for breast-milk feeding, through to comprehensive quality improvement programmes, and fostering team work and camaraderie. Oxygen monitoring is essential for very preterm infants receiving supplementary oxygen. The Neonatal Oxygenation Prospective Meta-analysis (NeOProM) collaboration has reported analysis of five trials of oxygen saturation (SpO2) targeting in very preterm infants and shown that a SpO2 target of 85-89% compared to 91-95% was associated with increased mortality (on average 28 extra deaths for every 1000 infants treated). Adopting a SpO2 target higher than 85-89% might increase the risk of ROP for some infants, highlighting the importance of pursuing all other means of prevention.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Middle-income countries; Oxygen saturation targeting; Prevention of morbidity; Randomised controlled trials; Retinopathy of prematurity; Very preterm infants

Mesh:

Substances:

Year:  2019        PMID: 31151776     DOI: 10.1053/j.semperi.2019.05.004

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  2 in total

1.  Current management of retinopathy of prematurity in sub-Saharan Africa.

Authors:  Trevor Lloyd; Sherwin Isenberg; Scott R Lambert
Journal:  J AAPOS       Date:  2020-06-04       Impact factor: 1.220

2.  Oxygen management among infants in neonatal units in sub-Saharan Africa: a cross-sectional survey.

Authors:  Scott K Herrod; Alex Stevenson; Yvonne E Vaucher; Scott R Lambert; Sherwin J Isenberg; Vivien L Yap; V Chinyere Ezeaka; Waldemar A Carlo
Journal:  J Perinatol       Date:  2021-03-26       Impact factor: 2.521

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.